Clinical Trial Update: Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

View source ↗

Summary

This clinical trial update presents long-term follow-up data from subjects treated with voretigene neparvovec-rzyl (AAV2-hRPE65v2) for inherited retinal dystrop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Retinal Dystrophy Due to Rpe65 Mutations

Drugs mentioned

• Luxturna (voretigene neparvovec-rzyl)

Snippet

Sponsor: Spark Therapeutics, Inc. | Conditions: Inherited Retinal Dystrophy Due to RPE65 Mutations | Status: ACTIVE_NOT_RECRUITING